The company projects revenue growth of mid- to high single digits in FY26 compared with an 8.5% increase in FY25 ...

The company also expects R&D spending to rise to 6–8% of sales, reflecting its commitment to pipeline expansion and ...

India’s largest drugmaker plans a $100 million push into US specialty drugs in FY26, even as it braces for regulatory ...

Detailed price information for Checkpoint Therapeutics Inc (CKPT-Q) from The Globe and Mail including charting and trades.

Metastatic colorectal cancer (mCRC) continues to pose a clinical and commercial challenge, with low 5-year survival rates and limited durable responses to existing therapies. While standard ...

Emrosi commercial launch initiated for the treatment of inflammatory lesions of rosacea in adults Fortress subsidiary Checkpoint Therapeutics to be acquired by Sun Pharma; special meeting of Checkpoin ...

The company also reported a planned acquisition of its subsidiary Checkpoint Therapeutics by Sun Pharmaceutical ... Fortress’ robust pipeline — including multiple late-stage programs and ...